|
Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
Jae-Woo Jung, Hae-Sim Park, Choon-Sik Park, Sang-Heon Cho, Inseon S. Choi, Hee-Bom Moon, Soon Seog Kwon, Ho Joo Yoon, Jung Won Park, Jong-Myung Lee, Dong-Chull Choi, Byoung Whui Choi
Korean J Intern Med. 2021;36(5):1260 Published online September 1, 2021
|
|
|
Allergy
Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
[corrected-article]
Jae-Woo Jung, Hae-Sim Park, Choon-Sik Park, Sang-Heon Cho, Inseon S. Choi, Hee-Bom Moon, Soon Seog Kwon, Ho Joo Yoon, Jung Won Park, Jong-Myung Lee, Dong-Chull Choi, Byoung Whui Choi
Korean J Intern Med. 2021;36(4):1001-1013. Published online June 1, 2021
Background/Aims: Omalizumab is the first biologic known to be effective in patients with severe allergic asthma.
Methods: This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 w..
|
|
|
Pulmonology
Clinical outcomes of extracorporeal membrane oxygenation support in patients with hematologic malignancies
Hye Seon Kang, Chin Kook Rhee, Hea Yon Lee, Young Kyoon Kim, Soon Seog Kwon, Seok Chan Kim, Jong Wook Lee
Korean J Intern Med. 2015;30(4):478-488. Published online June 29, 2015
Background/Aims: The clinical outcomes of patients with hematologic malignancies who were treated with extracorporeal membrane oxygenation (ECMO) after the failu re of optimal conventional therapy were determined.
Methods: The medical records of all patients administered ECMO during their stay in a..
|
|
|
